OBJECTIVES: Recent research is showing cardiovascular benefits of SGLT2 inhibitors. We aim to review and analyze the cardiovascular effects of canagliflozin (300 mg/day) among patients of type 2 diabetes mellitus. METHODS: We searched The Cochrane Library (CENTRAL), MEDLINE, DARE, and reference lists of articles for randomized controlled trials (RCTs) till 5^th January, 2018. Studies comparing the use of Canagliflozin with placebo or any other comparator in management of T2DM were included. The outcomes were effect on systolic and diastolic blood pressure (SBP and DBP), LDL-C, and HDL-C levels and number of deaths. Two authors independently searched and assessed the trial eligibility, risk of bias and extracted data. We summarized the dichotomous outcomes using risk ratios and continuous outcomes using mean differences (MD) and presented both measures with 95% confidence intervals (CI). RESULTS: We included ten RCTs. After 26 weeks, canagliflozin led to a significantly favorable effect on SBP and DBP and HDL-C levels (MD -5.37,95% CI [-6.36, -4.37], p<0.0001); (MD-2.74 [-3.37, -2.11], p<0.0001) and (MD 0.06 [0.04, 0.08], p<0.0001) respectively; and a non-favorable significant increase in LDL-C levels (MD 0.19 [0.12, 0.25],p<0.0001) as compared to placebo. After 52 weeks, there was significant decrease in SBP (-6.69 [-6.70, -6.68]; p<0.0001); a non-significant increase in LDL-C levels (0.05 [-0.08, 0.19]; p=0.42); and non-significant increase in HDL-C levels (0.05 [0.01, 0.08]; p=0.006) and a non-significantly lower risk of all mortality RR (0.60[0.24, 1.48], p=0.24) with canagliflozin as compared to placebo. After 52 weeks, canagliflozin led to a significant decrease in SBP (-4.85 [-6.11, -3.58]; p<0.0001); and non-significantly higher all cause mortality (RR 2.33 [0.35, 15.75]; p=0.38) as compared to sitagliptin 100 mg once daily. CONCLUSIONS: Canagliflozin leads to a significant decrease in SBP and DBP, after 26 and 52 weeks and a non-significant decrease in all-cause mortality after 52 weeks as compared to placebo.